Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Prasterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- Sponsors Endoceutics
- 07 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2018 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
- 10 May 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.